Evidence map›Paper›PMID 37809871›Full record

ArticleHeliyon2023

SARS-CoV-2 spike protein-derived immunogenic peptides that are promiscuously presented by several HLA-class II molecules and their potential for inducing acquired immunity.

Yuki Yajima, Akemi Kosaka, Takayuki Ohkuri, Yoshihiko Hirohashi, Dongliang Li, Takeshi Nagasaki, Toshihiro Nagato, Toshihiko Torigoe, Hiroya Kobayashi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuki YajimaDepartment of Oral and Maxillofacial Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Akemi KosakaDepartment of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Takayuki OhkuriDepartment of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Yoshihiko HirohashiDepartment of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Dongliang LiTsukuba Laboratory, Medical & Biological Laboratories Co., Ltd., Ina, Japan.
Takeshi NagasakiTsukuba Laboratory, Medical & Biological Laboratories Co., Ltd., Ina, Japan.
Toshihiro NagatoDepartment of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Toshihiko TorigoeDepartment of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Hiroya KobayashiDepartment of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current coronavirus disease 2019 (COVID-19) pandemic that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a significant threat to public health. Although vaccines based on the mRNA of the SARS-CoV-2 spike protein have been developed to induce both cellular and humoral immunity against SARS-CoV-2, there have been some concerns raised about their high cost, particularly in developing countries. In the present study, we aim to identify an immunogenic peptide in the SARS-CoV-2 spike protein to activate cellular immunity, particularly CD4

Indexed as

Cellular immunityHelper T lymphocytesSARS-CoV-2T-cell monitoring

Identifiers

PMID37809871
PMCPMC10559948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.